Terms: = Gastric cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
3 results:
1. Efficacy of Combined VEGFR1-3, PDGFα/β, and fgfr1-3 Blockade Using Nintedanib for Esophagogastric cancer.
Won E; Basunia A; Chatila WK; Hechtman JF; Chou JF; Ku GY; Chalasani SB; Boyar MS; Goldberg Z; Desai AM; Tuvy Y; Berger MF; Tang L; Kelsen DP; Schattner M; Ilson DH; Capanu M; Solit DB; Schultz N; Janjigian YY
Clin Cancer Res; 2019 Jul; 25(13):3811-3817. PubMed ID: 30952642
[TBL] [Abstract] [Full Text] [Related]
2. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract] [Full Text] [Related]
3. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
[TBL] [Abstract] [Full Text] [Related]
